“…In line with the pivotal ABVD DD‐DI trial (Russo et al , ), we confirm that a high response rate can be achieved also in patients with high‐risk features and support that intensification of the ABVD programme is feasible in ‘real‐life’ clinical practice, without a demanding management and burdening toxicity. In this regard, ABVD DD‐DI results may favourably match, in terms of CR rate, early PET‐negativity and acute toxicity, with those of escalated BEACOPP (Skoetz et al , ).…”